Assessing the accuracy of [18F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients

• Published in: EJNMMI research 2022-08, Vol.12 (1), p.48-48, Article 48
• Main Authors: Ingvar, Jacob, Hvittfeldt, Erland, Trägårdh, Elin, Simoulis, Athanasios, Bjartell, Anders
• Format: Article
• Language: English
• Subjects: Antigens; Cancer and Oncology; Cancer och onkologi; Cardiac Imaging; Clinical Medicine; Computed tomography; Fluorine isotopes; Imaging; Klinisk medicin; Lymph node dissection; Lymphatic system; Mathematical analysis; Medical and Health Sciences; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Metastases; Metastasis; Nuclear Medicine; Oncology; Original Research; Orthopedics; PET/CT; Positron emission; Prostate cancer; Radiochemical analysis; Radiology; Risk; Robotic surgery; Sensitivity analysis; Staging; Statistical analysis; Tomography; Urologi och njurmedicin; Urology and Nephrology
• ISSN: 2191-219X; 2191-219X
• DOI: 10.1186/s13550-022-00918-7

Background [ 18 F]PSMA-1007 is a promising tracer for integrated positron emission tomography and computed tomography (PET/CT). Objective Our aim was to assess the diagnostic accuracy of [ 18 F]PSMA-1007 PET/CT for primary staging of lymph node metastasis before robotic-assisted laparoscopy (RALP) with extended lymph node dissection (ePLND). Design, Setting and Participants The study was a retrospective cohort in a tertiary referral center. Men with prostate cancer that underwent surgical treatment for intermediate- or high-risk prostate cancer between May 2019 and August 2021 were included. Interventions [ 18 F]PSMA-1007 PET/CT for initial staging followed by RALP and ePLND. Outcome measurements and statistical analyses Sensitivity and specificity were calculated both for the entire cohort and for patients with lymph node metastasis ≥ 3 mm. Positive (PPV) and negative (NPV) predictive values were calculated. Results and limitations Among 104 patients included in the analyses, 26 patients had lymph node metastasis based on pathology reporting and metastases were ≥ 3 mm in size in 13 of the cases (50%). In the entire cohort, the sensitivity and specificity of [ 18 F]PSMA-1007 were 26.9% (95% confidence interval (CI); 11.6–47.8) and 96.2% (95% CI; 89.2–99.2), respectively. The sensitivity and specificity of [ 18 F]PSMA-1007 to detect a lymph node metastasis ≥ 3 mm on PET/CT were 53.8% (95% CI; 25.1–80.8) and 96.7% (95% CI; 90.7–99.3), respectively. PPV was 70% and NPV 93.6%. Conclusions In primary staging of intermediate- and high-risk prostate cancer, [ 18 F]PSMA-1007 PET/CT is highly specific for prediction of lymph node metastases, but the sensitivity for detection of metastases smaller than 3 mm is limited. Based on our results, [ 18 F]PSMA-1007 PET/CT cannot completely replace ePLND. Patient summary This study investigated the use of an imaging method based on a prostate antigen-specific radiopharmaceutical tracer to detect lymph node prostate cancer metastasis. We found that it is unreliable to discover small metastasis.